# Kaan Kavakli

List of Publications by Year
in descending order



| 65 | 1,530 | 361413 | 330143 |
|---|---|---|---|
| papers | citations | 20 h-index | 37 g-index |

| 65 | 65 | 65 | 1300 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | New Treatment Modalities in Hemophilia. Trends in Pediatrics, 2022, 3, 1-4. | 0.1 | 1 |
| 2 | Cost of hemophilia A in Turkey: an economic disease burden analysis. Journal of Medical Economics, 2021, 24, 1052-1059. | 2.1 | 4 |
| 3 | Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset. Blood Coagulation and Fibrinolysis, 2021, 32, 180-185. | 1.0 | 1 |
| 4 | Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Reviews, 2021, 50, 100833. | 5.7 | 6 |
| 5 | A Novel Molecular Indicator for Inhibitor Development in Haemophilia A. Journal of Pediatric Research, 2021, 8, 102-109. | 0.2 | 0 |
| 6 | Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study. Turkish Journal of Haematology, 2021, 38, 101-110. | 0.5 | 5 |
| 7 | Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia, 2020, 26, 64-72. | 2.1 | 17 |
| 8 | Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis, 2020, 18, 815-824. | 3.8 | 24 |
| 9 | Retrospective Evaluation of Childhood Cutaneous Mastocytosis Cases. Journal of Pediatric Research, 2020, 7, 13-17. | 0.2 | 0 |
| 10 | Factor 8 Gene Mutation Spectrum of 270 Patients with Haemophilia A: Identification of 36 Novel Mutations. Turkish Journal of Haematology, 2020, 37, 145-153. | 0.5 | 9 |
| 11 | Common themes and challenges in hemophilia care: a multinational perspective. Hematology, 2019, 24, 39-48. | 1.5 | 17 |
| 12 | Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood, 2019, 134, 1973-1982. | 1.4 | 103 |
| 13 | The impact of psychosocial determinants on caregiversâ€™ burden of children with haemophilia (results) Tj ETQq1 1 0.784314 rgBT /Ov | 2.1 | 13 |
| 14 | The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 2.1 | 16 |
| 15 | Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency. Blood Coagulation and Fibrinolysis, 2019, 30, 34-41. | 1.0 | 7 |
| 16 | Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia, 2019, 25, 60-66. | 2.1 | 32 |
| 17 | Clinical experience with moroctocog alfa (<scp>AF</scp>â€<scp>CC</scp>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. Haemophilia, 2018, 24, 604-610. | 2.1 | 5 |
| 18 | Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 2018, 58, 413-422. | 1.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Longâ€term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia, 2018, 24, e391-e394. | 2.1 | 15 |
| 20 | Haemophilia clinical care and research needs: Assessing priorities. Haemophilia, 2018, 24, e270-e273. | 2.1 | 0 |
| 21 | A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. Journal of Thrombosis and Haemostasis, 2018, 16, 2184-2195. | 3.8 | 56 |
| 22 | Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study. Turkish Journal of Haematology, 2018, 35, 129-133. | 0.5 | 2 |
| 23 | Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia, 2017, 23, 255-263. | 2.1 | 9 |
| 24 | Safety and effectiveness of room temperature stable recombinant factor <scp>VII</scp>a in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia, 2017, 23, 575-582. | 2.1 | 2 |
| 25 | Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307. | 2.5 | 56 |
| 26 | Real-World Early Treatment with Room Temperatureâ€“Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7â„¢ Post Hoc Analyses. TH Open, 2017, 01, e130-e138. | 1.4 | 1 |
| 27 | A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064. | 27.0 | 414 |
| 28 | Onceâ€weekly prophylactic treatment vs. onâ€demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia, 2016, 22, 381-388. | 2.1 | 41 |
| 29 | Current view and outcome of ITI therapy - A change over time?. Thrombosis Research, 2016, 148, 38-44. | 1.7 | 18 |
| 30 | Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia, 2016, 22, 419-425. | 2.1 | 25 |
| 31 | Pharmacokinetics of a highâ€purity plasmaâ€derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia, 2016, 22, 426-432. | 2.1 | 17 |
| 32 | Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7â„¢ Study. Blood, 2016, 128, 1439-1439. | 1.4 | 1 |
| 33 | Prophylaxis vs. onâ€demand treatment with BAY 81â€8973, a fullâ€length plasma proteinâ€free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis, 2015, 13, 360-369. | 3.8 | 74 |
| 34 | Prospective Evaluation of Whole Genome MicroRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia. BioMed Research International, 2014, 2014, 1-7. | 1.9 | 54 |
| 35 | Inhibitors to factor <scp>VII</scp> in congenital factor <scp>VII</scp> deficiency. Haemophilia, 2014, 20, e188-91. | 2.1 | 27 |
| 36 | Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B. Blood, 2014, 124, 1523-1523. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | RARE COAGULATION DISORDERS. Retrospective analyses of 156 patients in TURKEY. Turkish Journal of Haematology, 2012, 29, 48-54. | 0.5 | 11 |
| 38 | Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey. Haemophilia, 2012, 18, 383-391. | 2.1 | 20 |
| 39 | Micronucleus evaluation for determining the chromosomal breakages after radionuclide synovectomy in patients with hemophilia. Annals of Nuclear Medicine, 2012, 26, 41-46. | 2.2 | 7 |
| 40 | Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER,. Blood, 2011, 118, 3368-3368. | 1.4 | 0 |
| 41 | Longâ€term evaluation of chromosomal breakages after radioisotope synovectomy for treatment of target joints in patients with haemophilia. Haemophilia, 2010, 16, 474-478. | 2.1 | 15 |
| 42 | The value of early treatment in patients with haemophilia and inhibitors. Haemophilia, 2010, 16, 487-494. | 2.1 | 23 |
| 43 | Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia, 2010, 16, 902-909. | 2.1 | 33 |
| 44 | Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors. Blood, 2010, 116, 719-719. | 1.4 | 2 |
| 45 | Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study. Blood, 2010, 116, 720-720. | 1.4 | 13 |
| 46 | Radioisotope synovectomy with rhenium186in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia, 2008, 14, 518-523. | 2.1 | 40 |
| 47 | Long-term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience. Haemophilia, 2006, 12, 28-35. | 2.1 | 57 |
| 48 | Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.. Blood, 2006, 108, 4005-4005. | 1.4 | 1 |
| 49 | A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. Journal of Medical Economics, 2005, 8, 46-54. | 2.1 | 20 |
| 50 | Letter to the Editor: TREATMENT OF IRON-DEFICIENCY ANEMIA AND ERYTHROCYTE CATALASE ACTIVITY. Pediatric Hematology and Oncology, 2005, 22, 647-648. | 0.8 | 1 |
| 51 | PLASMA LEVELS OF THE VON WILLEBRAND FACTOR-CLEAVING PROTEASE IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS IN CHILDREN. Pediatric Hematology and Oncology, 2002, 19, 467-473. | 0.8 | 22 |
| 52 | Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease. Haemophilia, 2001, 7, 482-489. | 2.1 | 3 |
| 53 | SHOULD HEMOPHILIAC PATIENTS BE CIRCUMCISED?. Pediatric Hematology and Oncology, 2000, 17, 149-153. | 0.8 | 25 |
| 54 | NEUROPSYCHOLOGIC SEQUELAE IN THE LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Hematology and Oncology, 1999, 16, 213-220. | 0.8 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Intron 22 inversions in the Turkish haemophilia A patients: prevalence and haplotype analysis. Haemophilia, 1999, 5, 169-173. | 2.1 | 7 |
| 56 | Fibrin glue and clinical impact on haemophilia care. Haemophilia, 1999, 5, 392-396. | 2.1 | 25 |
| 57 | Circumcision and Haemophilia: a perspective. Haemophilia, 1998, 4, 1-3. | 2.1 | 26 |
| 58 | Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia, 1998, 4, 104-108. | 2.1 | 24 |
| 59 | Brief report. Plasma interleukin-3 (IL-3) and IL-7 concentrations in children with homozygous beta-thalassemia. Journal of Tropical Pediatrics, 1997, 43, 366-367. | 1.5 | 4 |
| 60 | Beta-Thalassemia Alleles in Aegean Region of Turkey: Effect on Clinical Severity of Disease. Pediatric Hematology and Oncology, 1997, 14, 59-65. | 0.8 | 8 |
| 61 | Serum Erythropoietin Levels in Patients with Beta Thalassemia Major and Intermedia. Pediatric Hematology and Oncology, 1997, 14, 161-167. | 0.8 | 19 |
| 62 | Termination of Transfusion Dependence in /J-Thalassemia: Two-Year Experience with Recombinant Human Erythropoietin. Pediatric Hematology and Oncology, 1997, 14, 285-287. | 0.8 | 2 |
| 63 | Specific Antibody Response in Children with Thalassemia Major. Pediatric Hematology and Oncology, 1997, 14, 181-183. | 0.8 | 1 |
| 64 | Safer and much cheaper circumcision using fibrin glue in severe haemophilia. Haemophilia, 1997, 3, 209-211. | 2.1 | 8 |
| 65 | A patient with WT syndrome and Castleman disease. Pediatrics International, 1995, 37, 108-112. | 0.5 | 3 |